The Apple Watch was able to detect irregular heart pulse rates that could signal the need for further monitoring for a serious heart rhythm problem, according to data from a large study funded by Apple Inc.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
Researchers at Indiana University developed a blood test that could help more accurately diagnose post-traumatic stress disorder.
Having second-degree or third-degree relatives with Alzheimer’s raises a person’s risk of developing the disease, a new study suggests.
Eli Lilly and Co.’s combination cancer treatment met the main goal of a late-stage clinical trial in testing on patients with a form of lung cancer, the drugmaker announced.
Shares of AMAG Pharmaceuticals plunged after the company’s Phase III PROLONG trial of Makena failed to show a statistically significant difference from placebo in preventing preterm births.
The old adage that drinking beer before wine prevents hangovers turns out to be a myth, German researchers say.
A new study shows first-time proof that AI can detect the severity of diabetic macular edema, which is a leading cause of blindness.
Allergan Plc’s experimental add-on treatment for depression failed three late-stage studies, casting doubts over the company’s drug pipeline and sending the Botox maker’s shares down nearly 4 percent.
An HIV-positive man in Britain became the second known adult worldwide to be cleared of the AIDS virus after he received a bone marrow transplant from an HIV resistant donor, his doctors said.
Novo Nordisk announced the results from a Phase IIIb trial comparing Ozempic (semaglutide) with an SGLT-2 inhibitor or placebo in adults with type 2 diabetes.